Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2024

Original Article

Immune checkpoint inhibitors and uveitis: the TriNetX population generation study

Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.

Frontiers in immunology

Citation & Authors

Front Immunol. 2023;14:1302293.

Hou-Ting Kuo; Chia-Yun Chen; Alan Y Hsu; Yu-Hsun Wang; Chun-Ju Lin; Ning-Yi Hsia; Yi-Yu Tsai; James Cheng-Chung Wei

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

purpose

To investigate the association between immune checkpoint inhibitor (ICI) use and incident uveitis in patients with cancer.

method

Cancer patients receiving ICIs and cancer controls not receiving ICIs were retrospectively identified from the TriNetX electronic health record registry, with incident uveitis as the primary outcome of interest. Bias was reduced through 1:1 propensity score matching. Multivariable Cox proportional hazards models and Kaplan–Meier methods evaluated risk.

result

Each group included 71,931 patients. In the ICI group, 54.7% were male, 76.5% were White, and the mean age at index was 63.6±12.2 years. In controls, 54.7% were male, 77% were White, and the mean age was 63.5±12.4 years. Kaplan–Meier curves showed significantly increased uveitis risk in the ICI group throughout follow-up (p<0.001); the HR over 144 months was 2.39 (95% CI 2.07–2.75). Risks of iridocyclitis, chorioretinal inflammation, retinal vasculitis, unspecified purulent endophthalmitis, panuveitis, and sympathetic uveitis were also increased. Subgroup analyses found higher uveitis hazard ratios after ICI use among patients younger than 65 and those aged 65 or older, both sexes, White and Asian patients, those with a smoking history, and those with hypertension or dyslipidemia. Monotherapy and combination analyses found increased risks with anti-PD-1 monotherapy (HR 1.98; 95% CI 1.65–2.37), anti-CTLA-4 monotherapy (5.86; 1.99–17.24), and anti-PD-1 plus anti-CTLA-4 (5.04; 3.55–7.16). Anti-PD-1 plus anti-PD-L1 did not show a significant risk increase (2.47; 0.81–7.50).

Conclusion

The ICI group showed a significantly higher risk of uveitis from the first year of follow-up. Greater vigilance for uveitis is warranted in patients with cancer receiving ICI therapy.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY ↗;Translations are subject to the same licensing conditions.